Skip to main content
ChemPartner PharmaTech Co., Ltd. logo

ChemPartner PharmaTech Co., Ltd. — Investor Relations & Filings

Ticker · 300149 ISIN · CNE100000Y27 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,256 across all filing types
Latest filing 2026-05-19 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300149

About ChemPartner PharmaTech Co., Ltd.

https://www.chempartner.com

ChemPartner PharmaTech Co., Ltd. is a global research and development organization providing comprehensive drug discovery and development services. Operating as a Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), the company supports pharmaceutical and biotechnology clients through an integrated service platform. Core capabilities include medicinal chemistry, biology, pharmacology, drug metabolism and pharmacokinetics (DMPK), and toxicology. The organization also offers specialized expertise in biologics discovery, protein engineering, and antibody development. ChemPartner facilitates the transition from early-stage research to clinical development through its pharmaceutical development and manufacturing capabilities, utilizing advanced technology to accelerate the discovery and production of novel therapeutic agents.

Recent filings

Filing Released Lang Actions
北京市竞天公诚律师事务所关于睿智医药科技股份有限公司2024年度向特定对象发行股票的补充法律意见书（三）（豁免版）
Regulatory Filings Classification · 78% confidence The document is a supplemental legal opinion (“补充法律意见书（三）”) provided by a law firm (JingTian & GongCheng) in connection with a 2024 targeted share issuance by the company. It is neither a financial report nor an announcement of voting results, dividends, or an earnings release. It does not contain financial statements itself but is part of the regulatory/prospectus-related materials for a capital-raising transaction. There is no dedicated category for legal opinion letters, so it falls under the general “Regulatory Filings” catch-all.
2026-05-19 Chinese
最近一年的财务报告及其审计报告
Audit Report / Information Classification · 95% confidence The document is titled “审计报告及财务报表” for the fiscal year ended December 31, 2025, contains the auditor’s opinion, basis for opinion, key audit matters, auditor and management responsibilities, followed by detailed financial statements (balance sheets, income statements, notes). It is a standalone audit report with financial statements rather than a full annual report, earnings release, or presentation. This matches the “Audit Report / Information” category.
2026-05-19 Chinese
关于向特定对象发行股票的募集说明书等申请文件更新的提示性公告
Share Issue/Capital Change Classification · 75% confidence The document is a public announcement by the company regarding updates to its application documents (prospectus, sponsor letter) for a proposed private placement of shares (“向特定对象发行股票”). It describes revisions to fundraising materials and next steps for regulatory approval. This is an announcement of a new share issue/capital change rather than a full financial report or AGM material. Accordingly, it falls under Share Issue/Capital Change (SHA).
2026-05-19 Chinese
中信证券股份有限公司关于睿智医药科技股份有限公司2024年度向特定对象发行股票之发行保荐书
Share Issue/Capital Change Classification · 90% confidence The document is a detailed sponsor’s report (“发行保荐书”) filed in connection with a directed share issuance to specific investors. It outlines the share placement terms, sponsor diligence, legal and regulatory compliance, and issuance structure. This is not an annual or interim financial report, earnings release, or simple announcement, but the formal issuance document for new share issuance. Under the taxonomy, it falls squarely under Share Issue/Capital Change (Code: SHA).
2026-05-19 Chinese
2024年度向特定对象发行股票募集说明书(申报稿)
Share Issue/Capital Change Classification · 90% confidence The document is a detailed “募集说明书 (prospectus)” for a 2024 private placement of A‐shares to specific investors, covering issuance terms, pricing, quantity, risk factors, use of proceeds, board approvals and regulatory requirements. It is not a brief announcement nor a financial report or earnings release, but a formal offering document related to new share issuance. This corresponds to the “Share Issue/Capital Change” category (SHA).
2026-05-19 Chinese
中信证券股份有限公司关于睿智医药科技股份有限公司2024年度向特定对象发行股票之上市保荐书
Share Issue/Capital Change Classification · 85% confidence The document is the full “上市保荐书” (Listing Sponsorship Letter) prepared by the sponsor (underwriter) for a targeted share issuance and listing of ChemPartner PharmaTech. It contains detailed sections on the issuance plan (stock type, pricing, quantity, use of proceeds), full company background, financials, risk factors, sponsor due diligence and legal disclosures. This is not merely an earnings release or report announcement but the core prospectus-like issuance document for a new share issue. Among the defined categories, it best fits “Share Issue/Capital Change” (SHA).
2026-05-19 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.